Open mitochondrial research · Plain-language explainer

Published on Zenodo · October 2, 2026

Mitochondrial transfer evidence separates acute rescue from durable organelle replacement

Friedl, Andrew

Abstract

Background: Mitochondrial transfer and mitochondrial transplantation are increasingly described as routes to repair bioenergetic injury, but delivery, uptake, targeting, acute rescue, and durable organelle replacement are often compressed into one claim. Objective: This working paper tested whether primary evidence supports a general durable-replacement interpretation or a narrower acute-rescue interpretation with explicit delivery-specificity gates. Methods: Primary studies were screened through 1 October 2026 using PubMed, PMC, publisher pages, and DOI records. Eligible records directly measured mitochondrial transfer, transplantation delivery, recipient uptake, bioenergetics, organ function, clinical feasibility, safety, or targeting specificity. Endpoints, claim maturity, and boundary conditions were coded before efficacy language was assigned. Results: Across nine primary studies, the most consistent support was for context-specific delivery, uptake, targeting advances, and acute rescue. Cell and animal studies showed uptake-linked macrophage phagocytosis, reduced cardiac infarct size, improved lung mechanics, targeted donor-mitochondria internalization and neuronal survival, and transcriptomic/proteomic movement after ischemia-reperfusion injury. Human studies supported feasibility and short-window safety in pediatric cardiac shock and phase 1 acute stroke settings, but neither design proves efficacy. Durability remained the main boundary: cardiomyocyte bioenergetic gains returned to baseline after an early increase, targeted delivery did not constitute a patient efficacy test, and myeloid-cell replacement evidence involved a broader cell-therapy intervention. The accompanying repository deposit provides source data, analysis code, figure source material, claim-verification records, and checksums for the PDF and editable DOCX. Conclusions: Current evidence supports mitochondrial transfer as a biologically plausible acute rescue or cell-mediated support mechanism in selected contexts. It does not yet support a general claim of durable organelle replacement.

Download the manuscript PDF

DOI: 10.5281/zenodo.23111297

Read the full paperRead the public summary

The paper at a glance

The question

Mitochondria are cell structures that make usable energy. Some researchers are testing whether healthy mitochondria can be moved into injured tissues. This could matter for sudden injury, but the evidence must not be stretched into treatment advice.

Main takeaway

The strongest evidence supports short-term rescue signals after injury. Some studies showed better cell function, smaller heart injury in animals, improved lung mechanics in mice, targeted delivery to selected cell types, or feasible delivery in people. A cell study also showed that early energy gains faded over time.

Important caution

The evidence does not show that transferred mitochondria permanently replace damaged mitochondria in people. It also does not prove that mitochondrial transplantation is an effective treatment for stroke, heart disease, lung injury, or inherited mitochondrial disease.

Why this matters

Mitochondria are cell structures that make usable energy. Some researchers are testing whether healthy mitochondria can be moved into injured tissues. This could matter for sudden injury, but the evidence must not be stretched into treatment advice.

How the research was done

The paper reviewed primary studies in cells, animals, targeted-delivery systems, donated-organ models, children with severe heart injury after surgery, and a small phase 1 stroke setting.

What the researchers found

The strongest evidence supports short-term rescue signals after injury. Some studies showed better cell function, smaller heart injury in animals, improved lung mechanics in mice, targeted delivery to selected cell types, or feasible delivery in people. A cell study also showed that early energy gains faded over time.

What this does not prove

The evidence does not show that transferred mitochondria permanently replace damaged mitochondria in people. It also does not prove that mitochondrial transplantation is an effective treatment for stroke, heart disease, lung injury, or inherited mitochondrial disease.

What researchers should test next

Better studies need to track how long transferred mitochondria persist, whether they keep working, which patients might benefit, and whether outcomes improve beyond usual care.

Helpful definitions

Key terms in plain English

MitochondriaStructures inside cells that convert fuel into energy the cell can use.

See the evidence

Visual findings

Visual finding 1. Analysis process figure
Visual finding 2. Concept summary figure

For non-specialists

What this could mean for patients and families

This work should be read as research synthesis, not medical guidance. People should not seek mitochondrial transfer or transplantation outside ethically reviewed clinical research.

  • Was the study done in people, animals, or cells?
  • Did it measure patient outcomes or only cell and biomarker changes?
  • How long did the transferred mitochondria appear to work?
  • Was there a comparison group receiving usual care?
Create your Mito Map →Join Mito Map as a researcher →